This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks With 100% Buy Ratings

10. BioDelivery Sciences International (BDSI - Get Report) is development-stage, specialty pharmaceutical company using licensed and proprietary drug delivery technologies to develop and commercialize new therapeutic formulations.

BioDelivery recently refuted a patent infringement lawsuit filed by MonoSol RX. In a press release, Dr. Mark A. Sirgo, president and CEO, said, "Our manufacturing process for ONSOLIS, which MonoSol asserts infringes its process patent, is a trade secret for which no one has any access. MonoSol has failed to disclose any basis for its assertion that our confidential, proprietary manufacturing process infringes its newly-issued patent." He added, "Importantly, we have not and will not allow this meritless claim to distract us from driving our promising development pipeline forward including our aggressive pursuit of BEMA Buprenorphine for the treatment of chronic pain and BEMA Buprenorphine/Naloxone for the treatment of opioid dependence."

The stock will likely provide an upside of 91% over the next 12 months with a consensus target price of $6.3, according to analysts polled by Bloomberg. In comparison, Hospira (HSP), Watson Pharmaceuticals (WPI), Cephalon (CEPH), King Pharmaceuticals (KG) and Akorn (AKRX) are likely to return around 27%, 8%, 24%, -5% and 45%, respectively.

All the four analysts covering the stock recommend buying.

2 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
ATHX $1.29 0.00%
BDSI $9.26 0.00%
CPHI $0.38 0.00%
MNOV $4.09 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs